Platelet Activation

• 

  Subject Areas on Research

  • A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. 
  • A freeze on tailored antiplatelet therapy? 
  • A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity. 
  • A possible mechanism of action of activated factor VII independent of tissue factor. 
  • Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. 
  • Adhesion molecules, platelet activation, and cardiovascular risk. 
  • An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial. 
  • Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention. 
  • Anticoagulant therapy for percutaneous coronary intervention. 
  • Antiplatelet resistance--fact or myth? 
  • Antiplatelet therapy after implantation of drug-eluting stents: duration, resistance, alternatives, and management of surgical patients. 
  • Aspirin resistance. 
  • Assessment of platelet activity by measuring platelet-derived substances in plasma from patients with acute myocardial infarction: surprising lessons from the GUSTO-III Platelet Study. 
  • Assessment of primary hemostasis by PFA-100 analysis in a tertiary care center. 
  • Atomic description of the immune complex involved in heparin-induced thrombocytopenia. 
  • Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. 
  • Biomarkers in atrial fibrillation: investigating biologic plausibility, cause, and effect. 
  • Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. 
  • Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. 
  • Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. 
  • Cardiopulmonary bypass induces leukocyte-platelet adhesion. 
  • Cardiovascular devices and platelet interactions: understanding the role of injury, flow, and cellular responses. 
  • Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study. 
  • Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies. 
  • Clinical applications of antiplatelet therapy. 
  • Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. 
  • Clopidogrel: the future choice for preventing platelet activation during coronary stenting? 
  • Comparison of early platelet activation in patients undergoing on-pump versus off-pump coronary artery bypass surgery. 
  • Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. 
  • Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. 
  • Contemporary use of platelet function and pharmacogenomic testing among patients with acute myocardial infarction undergoing percutaneous coronary intervention in the United States. 
  • Could stent design affect platelet activation? Results of the Platelet Activation in STenting (PAST) Study. 
  • Current evidence and clinical implications of aspirin resistance. 
  • Dark chocolate effect on platelet activity, C-reactive protein and lipid profile: a pilot study. 
  • Determinants of PF4/heparin immunogenicity. 
  • Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials. 
  • Does Platelet Reactivity Predict Bleeding in Patients Needing Urgent Coronary Artery Bypass Grafting During Dual Antiplatelet Therapy? 
  • Does heart failure etiology, New York Heart Association class, or ejection fraction affect the ability of clopidogrel to inhibit heightened platelet activity? 
  • Does increased platelet release of Abeta peptide contribute to brain abnormalities in individuals with depression? 
  • Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. 
  • Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor. 
  • Effect of intravenous lidocaine on the transcerebral inflammatory response during cardiac surgery: a randomized-controlled trial. 
  • Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery disease. 
  • Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. 
  • Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk. 
  • Elevation in plasma Abeta42 in geriatric depression: a pilot study. 
  • Enhanced platelet/endothelial activation in depressed patients with acute coronary syndromes: evidence from recent clinical trials. 
  • Evaluating the clinical usefulness of platelet function testing: considerations for the proper application and interpretation of performance measures. 
  • Evaluation of platelets in heart failure: is platelet activity related to etiology, functional class, or clinical outcomes? 
  • Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. 
  • Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis. 
  • Failure of platelet parameters and biomarkers to correlate platelet function to severity and etiology of heart failure in patients enrolled in the EPCOT trial. With special reference to the Hemodyne hemostatic analyzer. Whole Blood Impedance Aggregometry for the Assessment of Platelet Function in Patients with Congestive Heart Failure. 
  • Hemostatic abnormalities in patients with congestive heart failure: diagnostic significance and clinical challenge. 
  • Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome. 
  • Heparin-induced thrombocytopenia and cardiac surgery. 
  • Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA. 
  • Heparin-induced thrombocytopenia: pathophysiology and management. 
  • High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. 
  • Hydrogen peroxide promotes aging-related platelet hyperactivation and thrombosis. 
  • Immunity to thrombotic events is achievable if we stop the guessing game: is this the major hidden message from GRAVITAS? 
  • Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. 
  • Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease: an historical account. 
  • Inflammation and circulating endothelial progenitor cells in patients with coronary artery disease and residual platelet reactivity. 
  • Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease. 
  • Influence of platelet reactivity and inflammation on peri-procedural myonecrosis in East Asian patients undergoing elective percutaneous coronary intervention. 
  • Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention. Results of the ACCEL-BLEED study. 
  • Initial platelet activity may predict efficacy after chronic oral glycoprotein IIb/IIIa blockade: should we still consider uniform treatment regimens? 
  • Interpretation of platelet inhibition by clopidogrel and the effect of non-responders. 
  • Is there a rationale for antiplatelet therapy in acute heart failure? 
  • LAT is required for tyrosine phosphorylation of phospholipase cgamma2 and platelet activation by the collagen receptor GPVI. 
  • Moderate alcohol consumption is associated with decreased platelet activity in patients presenting with acute myocardial infarction. 
  • Modulation of platelet surface adhesion receptors during cardiopulmonary bypass. 
  • Neutrophil extracellular traps are pathogenic in primary graft dysfunction after lung transplantation. 
  • Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction: The REMODELING Trial. 
  • PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact. 
  • Pathogenesis of heparin-induced thrombocytopenia and thrombosis. 
  • Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention. 
  • Pharmacodynamic effects of cilostazol versus clopidogrel in stented patients under proton pump inhibitor co-administration: the ACCEL-PARAZOL study. 
  • Pharmacology of antiplatelet agents. 
  • Platelet PlA2 polymorphism and platelet activation are associated with increased troponin I release after cardiopulmonary bypass. 
  • Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation: From the ADAPT-DES Study. 
  • Platelet activation after stenting with heparin-coated versus noncoated stents. 
  • Platelet activation and its patient-specific consequences. 
  • Platelet activation and pneumonia: is soluble p-selectin the right marker? 
  • Platelet activation in myocardial ischemic syndromes. 
  • Platelet activation in patients with congestive heart failure: do we have enough evidence to consider clopidogrel? 
  • Platelet activation in patients with thrombotic thrombocytopenic purpura. 
  • Platelet activity of high-dose factor VIIa is independent of tissue factor. 
  • Platelet binding and activity of recombinant factor VIIa. 
  • Platelet function and fibrinolytic agents: two sides of a coin? 
  • Platelet function and total length of intracoronary stents: is there a correlation? 
  • Platelet heterogeneity: variation in coagulation complexes on platelet subpopulations. 
  • Platelet monitoring for PCI: is it really necessary? 
  • Platelet procoagulant complex assembly in a tissue factor-initiated system. 
  • Platelet reactivity during ticagrelor maintenance therapy: a patient-level data meta-analysis. 
  • Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. 
  • Platelet-dependent action of high-dose factor VIIa. 
  • Platelet-derived CD154: ultrastructural localization and clinical correlation in organ transplantation. 
  • Platelet-derived or soluble CD154 induces vascularized allograft rejection independent of cell-bound CD154. 
  • Platelet-mediated thrombosis and drug-eluting stents. 
  • Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. 
  • Platelets from thrombocytopenic ponies acutely infected with equine infectious anemia virus are activated in vivo and hypofunctional. 
  • Post-coronary intervention recurrent ischemia in the presence of adequate platelet inhibition by dual antiplatelet therapy: what are we overlooking? 
  • Prasugrel. 
  • Promises of PAR-1 inhibition in acute coronary syndrome. 
  • Properties of procoagulant platelets: defining and characterizing the subpopulation binding a functional prothrombinase. 
  • Protamine-induced immune thrombocytopenia. 
  • Randomized safety studies of intravenous perflubron emulsion. I. Effects on coagulation function in healthy volunteers. 
  • Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitor. 
  • Relation of platelet activation and myocardial ischemia biomarkers dependent on type of chest pain (abrupt onset versus intermittent) in patients with angina pectoris or non-Q-wave acute myocardial infarction. 
  • Relationship between age and platelet activation in patients with stable and unstable angina. 
  • Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosis. 
  • Resistance to antiplatelet drugs: current status and future research. 
  • Role of C3 cleavage in monocyte activation during extracorporeal circulation. 
  • Role of prostacyclin in the cardiovascular response to thromboxane A2. 
  • S-nitrosoglutathione/glutathione disulphide/Cu2+-dependent stimulation of L-arginine transport in human platelets. 
  • Safety profile of recombinant factor VIIa. 
  • Selective blockade of membrane attack complex formation during simulated extracorporeal circulation inhibits platelet but not leukocyte activation. 
  • Sex differences in platelet reactivity and cardiovascular and psychological response to mental stress in patients with stable ischemic heart disease: insights from the REMIT study. 
  • Superactivated platelets: thrombus regulators, thrombin generators, and potential clinical targets. 
  • Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin. 
  • The concordance and correlation of measurements by multiple electrode and light transmittance aggregometries based on the pre-defined cutoffs of high and low on-treatment platelet reactivity. 
  • The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. 
  • The effects of activated factor VII in a cell-based model for tissue factor-initiated coagulation. 
  • The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. 
  • The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor. 
  • The role of platelet function testing and genotyping in the stented patient treated with clopidogrel. 
  • The stratification of platelet reactivity and activation in patients with stable coronary artery disease on aspirin therapy. 
  • Thrombin activates factor XI on activated platelets in the absence of factor XII. 
  • Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555. 
  • Thrombin receptor. Variations on a theme. 
  • Thrombogenesis in atrial fibrillation: contributing mechanisms and natural history. 
  • Time dependence of clopidogrel loading effect: platelet activation versus platelet aggregation. 
  • Transcerebral platelet activation after aortic cross-clamp release is linked to neurocognitive decline. 
  • Transmission of a procoagulant signal from tissue factor-bearing cell to platelets. 
  • Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. 
  • Understanding the dynamics of thrombin in cardiovascular disease: pathobiology and biochemistry for the clinician. 
  • Uniform platelet activation exists before coronary stent implantation despite aspirin therapy. 
  • Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure. 
  • Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y(12) receptor inhibitors and high on-treatment platelet reactivity. 
  • Variability in platelet procoagulant activity in healthy volunteers. 
  • Viral respiratory tract infections increase platelet reactivity and activation: an explanation for the higher rates of myocardial infarction and stroke during viral illness. 
  • What does cerebral platelet activation mean in the setting of carotid stenosis? 
• 

  Keywords of People

  • Hoffman, Maureane, Professor of Pathology, Immunology
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. / Guidant Foundation Professor of Cardiology, Medicine, Clinical Pharmacology